Epigral Ltd AI Stock Analysis
Want to see IN:EPIGRAL full AI Analyst Report?
Epigral Ltd (EPIGRAL) AI Stock Analysis
Epigral Ltd
(NSE:EPIGRAL)
Epigral Ltd receives a moderate overall score, heavily supported by its strong balance sheet, aggressive debt reduction, and a fair valuation multiple. However, the score is significantly weighed down by poor technical momentum, with the stock trading below all major moving averages. Fundamentally, while long-term top-line growth is impressive, recent gross margin compression and poor free cash flow conversion present near-term risks that limit upward scoring.
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 40.44B
- Dividend Yield
- 0.53%
- Average Volume (3M)
- 3,172
- Price to Earnings (P/E)
- 14.4
- Beta (1Y)
- 1.18
- Revenue Growth
- 12.89%
- EPS Growth
- -29.38%
- Country
- India
- Employees
- 1,135
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlo...
How the Company Makes Money
EPIGRAL makes money mainly by selling chemical products to business customers (B2B) in the textile manufacturing ecosystem. Its core revenue streams typically include: (1) sales of textile auxiliaries and processing chemicals (e.g., pretreatment, dye...
Epigral Ltd Financial Statement Overview
Summary
Financials are anchored by a fortress balance sheet with significantly reduced debt-to-equity. However, recent gross margin compression and volatile, occasionally negative free cash flows present notable headwinds despite reliable net profitability.
Income Statement
72PositiveBalance Sheet
92Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.85B | 24.95B | 25.50B | 18.94B | 21.69B | 15.50B |
| Gross Profit | 6.72B | 4.63B | 10.67B | 7.79B | 6.43B | 7.48B |
| EBITDA | 5.91B | 5.50B | 7.11B | 4.77B | 6.81B | 5.01B |
| Net Income | 2.85B | 3.32B | 3.58B | 1.96B | 3.53B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 35.85B | 35.05B | 31.52B | 27.94B | 24.32B | 21.24B |
| Cash, Cash Equivalents and Short-Term Investments | 70.50M | 54.60M | 965.00M | 31.83M | 142.40M | 250.85M |
| Total Debt | 5.70B | 5.72B | 5.93B | 9.64B | 8.79B | 9.93B |
| Total Liabilities | 12.21B | 12.84B | 12.48B | 15.40B | 13.63B | 13.98B |
| Stockholders Equity | 23.65B | 22.21B | 19.05B | 12.54B | 10.69B | 7.26B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -65.30M | 2.46B | -7.90M | 2.10B | -1.72B |
| Operating Cash Flow | 0 | 3.88B | 4.41B | 3.98B | 6.26B | 2.84B |
| Investing Cash Flow | 0 | -3.55B | -2.62B | -4.01B | -4.37B | -4.55B |
| Financing Cash Flow | 0 | -457.90M | -1.64B | -75.98M | -2.00B | 1.95B |
Epigral Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Neutral. The current price of 942.25 is above the 20-day moving average (MA) of 921.55, below the 50-day MA of 1006.96, and below the 200-day MA of 1062.32, indicating a neutral trend. The MACD of -15.56 indicates Negative momentum. The RSI at 47.70 is Neutral, neither overbought nor oversold. The STOCH value of 71.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
Overall Rating
IN:EPIGRAL66Neutral
IN:VALIANTORG63Neutral
IN:INDOAMIN62Neutral
IN:DEEPAKNTR56Neutral
IN:GUJALKALI54Neutral
IN:STYRENIX54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | INR 40.65B | 14.37 | ― | 0.53% | 12.89% | -29.38% | |
| 63Neutral | INR 9.61B | 14.64 | ― | ― | 21.32% | 175.87% | |
| 62Neutral | INR 8.18B | 10.15 | ― | 0.44% | 22.17% | 1.86% | |
| 56Neutral | INR 216.86B | 20.07 | ― | 0.48% | 25.13% | 99.89% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 43.40B | 32.07 | ― | 3.06% | 11.16% | 88398.04% | |
| 54Neutral | INR 32.55B | 12.95 | ― | 2.48% | 9.70% | 25.33% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:EPIGRAL | Epigral Ltd | 942.25 | -509.83 | -35.11% | |
| IN:DEEPAKNTR | Deepak Nitrite Limited | 1561.25 | -122.76 | -7.29% | |
| IN:GUJALKALI | Gujarat Alkalies & Chemicals Ltd. | 579.10 | 47.77 | 8.99% | |
| IN:INDOAMIN | Indo Amines Limited | 112.70 | -12.84 | -10.23% | |
| IN:STYRENIX | Styrenix Performance Materials Ltd | 1850.95 | -145.87 | -7.31% | |
| IN:VALIANTORG | Valiant Organics Limited | 342.95 | 74.25 | 27.63% |
Epigral Ltd Corporate Events
Epigral Secures CRISIL AA/Stable and A1+ Ratings on ₹1,050 Crore Bank Facilities
Epigral Limited has disclosed that CRISIL Ratings has revised its credit ratings on the company’s bank loan facilities totaling Rs 1,050 crore. The long-term bank facilities have been assigned a CRISIL AA/Stable rating, while the short-term facilitie...
Epigral to Hold Q2 FY27 Earnings Call on November 2
Epigral Limited has scheduled a conference call on Monday, November 2, 2026, at 5:00 p.m. IST to discuss its financial results for the second quarter of fiscal year 2027 with investors and analysts. The company informed the National Stock Exchange of...
Epigral to Host Investor and Analyst Plant Visit at Dahej Facility
Epigral Ltd has announced that Elara Securities (India) Pvt Ltd will conduct an investor and analyst visit to the company’s manufacturing plant in Dahej, Gujarat, on 22 October 2026, with the schedule subject to change based on operational or partici...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026
